Johnson and Johnson Has Paid $BILLIONS in Criminal Settlements and Never Produced a Vaccine Before – Why Would We Trust Them for a New Experimental COVID Vaccine?

From its humble beginnings in the 1880s, making cotton gauze dressings and eventually band aids, baby powder and shampoo, J&J has expanded into one of the most powerful multinational pharmaceutical and medical device companies in the world.  But how is it that a drug and household health product company, with no prior history in vaccine development, can develop and rush to market its first vaccine against a viral strain that was only identified 14 months ago?  Developing a vaccine requires many years and necessitates the establishment of an R&D infrastructure vastly different than conventional drug development.  The other major companies developing Covid-19 vaccines have been in the business for decades. But not J&J. There is something more to this story that demands investigation. And if the company’s long rap sheet offers any warning, it is that we must be wary of any claims J&J publicly states about the efficacy and safety of its products. Especially when the pandemic promises to increase the profits of numerous shareholders.

FDA is Mind-Numbing America: Psychotropic Drugs and Electroshock Approval Boosts $35B Industry

The Food and Drug Administration (FDA) is considering approving Johnson & Johnson’s new nasal spray antidepressant, esketamine (Spravato) after an FDA advisory committee voted on February 12, 2019 in its favor. The drug is a chemical mirror of ketamine, a potent “dissociative anesthetic” that is abused as the illegal “club drug,” Special K, and generates an intense high and euphoric effects, and hallucinations. If approved, it would add to the mind-numbing of America that an FDA-psychiatric collusion is causing, says the Citizens Commission on Human Rights (CCHR). The group said the FDA’s continuing clearance of potentially addictive and dangerous psychotropic drugs and, more recently, electroshock treatment devices, fuels a lucrative $35 billion a year industry at the cost of consumers’ mental health and lives. Astoundingly, with more than 43.6 million Americans each year now taking antidepressants once touted as “miracle pills,” psychiatrists now claim that the drugs don’t work in one out of every three people taking them.